Alas, another trial and still no answer. This well-conceived and well-conducted randomized trial fuels the debate and leaves us where we started. All 8 published trials examining the use of prophylactic octreotide have their differences in design and outcome, but the most compelling finding is the transatlantic discord: the European trials favor the use of octreotide, whereas the American trials do not. Because of this it is still not possible to state that administration of prophylactic octreotide is a standard of care following pancreatic resection.
Windsor JA. Octreotide in the Prevention of Intra-abdominal Complications Following Elective Pancreatic Resection—Invited Critique. Arch Surg. 2004;139(3):295. doi:10.1001/archsurg.139.3.295